Dr. Mark Ware joins Canopy Growth Corporation as Chief Medical Officer

Photo credit: www.canopygrowth.com
Posted on: May 28, 2018

Submitted

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NYSE:CGC) is pleased to announce that Dr. Mark Ware, a leading researcher in the cannabis field for decades, will join the senior leadership team at Canopy Growth as the Company’s Chief Medical Officer commencing July 1st, 2018.

Dr. Ware is an associate professor of family medicine and anesthesia at McGill University. Over a period of 20 years he has established himself as a dedicated researcher and thought leader in advancing the medical community’s understanding of cannabis and cannabinoids. His research has focused on the safety, efficacy and effectiveness of cannabis and cannabinoids in pain and symptom management, and dates back well before the days of commercial cannabis production. He served for ten years as Executive Director of the nonprofit Canadian Consortium for the Investigation of Cannabinoids (CCIC), and is also a longstanding Board Member of the International Association for Cannabinoid Medicines. In 2016, Dr. Ware served as vice-chair of the Government of Canada’s Task Force on Cannabis Legalization and Regulation. Dr Ware will take a leave of absence from McGill University to pursue this opportunity.

“Bringing Dr. Mark Ware into a senior position within Canopy Growth demonstrates our commitment to building a well-funded, carefully refined global clinical research plan to develop new evidence, markets and products as it related to cannabis,” said Bruce Linton, Chairman & CEO, Canopy Growth. “His knowledge and expertise strengthen our ability to research and develop sophisticated cannabis medicines capable of improving patients’ lives around the world, while providing further clinical evidence as healthcare practitioners and governments are calling for.”

In his role as Chief Medical Officer, Dr. Ware will lead Canopy Growth’s global clinical research strategy, while also assisting in medical education and all aspects of ensuring the Company builds a world-class medical division centered around its global medical business, Spectrum Cannabis.

“I am very excited about the opportunity to join Canopy and to further develop global cannabis research” said Dr. Ware. “This approach is needed to more effectively respond to the needs of patients and health care professionals worldwide.”

The appointment of Dr. Ware follows on the heels of Canopy Growth’s announcement that it intends to acquire all outstanding shares in its affiliated cannabis research arm, Canopy Health Innovations Inc., including ownership in the recently established Oxford-based Beckley Canopy Therapeutics, a partnership with the renowned Beckley Foundation. Through strong research, drug development and clinical capabilities, along with a growing IP portfolio and top-tier management, Canopy is committed to a successful global medical cannabis industry.

Here’s to Future Growth (and welcome, Dr. Mark Ware!).